Pyridostatin Trifluoroacetate Salt

Catalog No.C12691 Batch:C1269103

Product Datasheet

Technical Data

Formula	$C_{31}H_{32}N_8O_5 \cdot C_2HF_3O_2$					
Molecular Weight	710.7	**CAS No.**	1472611-44-1			
Solubility (25°C)*	In vitro	DMSO	100 mg/mL (140.7 mM)			
		Water	30 mg/mL (42.21 mM)			
		Ethanol	9 mg/mL (12.66 mM)			
	In vivo (Add solvents to the product individually and in order)	Oral Administration	Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Capsid Bio tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped at 2-8°C for storage purposes.)

Preparing Stock Solutions

Biological Activity

Description	Pyridostatin Trifluoroacetate Salt is a **G-quadruplexe** stabilizer with **K_d** of 490 nM in a cell-free assay, which targets a series of proto-oncogenes.
Targets	G-quadruplexe [1] (Cell-free assay) 490 nM(Kd)
In vitro	Pyridostatin decreases the proliferation of MRC-5–SV40 cells and various cancer cell lines, and induces cell-cycle arrest by DNA-damage checkpoint activation. Pyridostatin also reduces SRC-dependent cell motility in MDA-MB-231 cells by interacting with G-quadruplex motifs in SRC. [2] Pyridostatin decreases EBNA1 synthesis via inhibition of G-quadruplexes. [3]
In vivo	

Protocol (from reference)

Cell Assay:[2]

- **Cell lines**
  MRC-5–SV40 cells and various cancer cell lines
- **Concentrations**
  10 μM
- **Incubation Time**
  48 h
- **Method**
  Cells are plated at equal confluence and are left either untreated or were treated with 2 μM pyridostatin continually during the indicated time before harvesting the cells. Cells from individual plates are trypsinized and counted in a Coulter counter. Graphs represent the total cell numbers at each time interval, and the error bars represent the s.e.m. Data represent three independent experiments.

Animal Study:[4]

- **Animal Models**
  CB17-SCID mice
- **Dosages**
  7.5 mg/kg
- **Administration**
  i.v.

References

https://pubmed.ncbi.nlm.nih.gov/21941250/ https://pubmed.ncbi.nlm.nih.gov/22306580/ https://pubmed.ncbi.nlm.nih.gov/24633353/

+ Expand

RETURN POLICY

Capsid Bio's Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING & STORAGE

Capsid Bio products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Capsid Bio Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Capsid Bio products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

EU Headquarters
Gajeva ulica 28, HR-10000 Zagreb, Croatia

US Headquarters
12222 Merit Dr STE 130 Dallas, Texas, 75251

UK Headquarters
121 ABILITY HOUSE, BROOKER ROAD, EN9 1JH, ESSEX

Orders: Sales@capsidbio.com
Enquiries: info@capsidbio.com
www.capsidbio.com